Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 10/20 | 0.63 |
| ▸ | NPC1 | O15118 | 9/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.63 |
| ▸ | HPGD | P15428 | 6/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.63 |
| ▸ | MAPT | P10636 | 4/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.63 |
| ▸ | CASP1 | P29466 | 1/20 | 0.63 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.56 |
| ▸ | RELA | Q04206 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7564852 | 0.87 | RAB9A (0.79) | RAB9ANPC1SMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL1022959 | 0.86 | RAB9A (0.68) | RAB9ANPC1SMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL29892760 | 0.85 | RAB9A (0.67) | RAB9ANPC1SMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL7564856 | 0.84 | RAB9A (0.70) | RAB9ANPC1SMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL13387589 | 0.83 | RAB9A (0.72) | RAB9ANPC1SMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL3765824 | 0.83 | RAB9A (0.69) | RAB9ANPC1SMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL12637645 | 0.82 | RAB9A (0.67) | RAB9ANPC1SMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL8866622 | 0.82 | RAB9A (0.63) | RAB9ANPC1SMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL12637646 | 0.82 | RAB9A (0.68) | RAB9ANPC1SMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL16696426 | 0.82 | RAB9A (0.68) | RAB9ANPC1SMN1; SMN2HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040101864-A1 | Chemical process | ATRAZENECA AB (SE) | 2004-05-27 | — | — | US | disclosed |
| WO-2003051909-A2 | PROCESS FOR THE MANUFACTURE OF PHARMACEUTICALLY ACCEPTABLE SALTS OF A COMPOUND | ASTRAZENECA AB (SE) | 2003-06-26 | — | — | WO | disclosed |
| WO-2003051918-A1 | SOLUTION-PHASE PROCESS FOR THE MANUFACTURE OF DECAPEPTIDE | ASTRAZENECA AB (SE) | 2003-06-26 | — | — | WO | disclosed |
| EP-1320538-A2 | PROCESS FOR THE PREPARATION OF 5-PHENYLPENTANOYL-ALA-ARGL-ALA- 2-[3-AMINO-2-OXOPYRROLIDIN-1-YL]PROPIONYL - ALA-ARG-ALA-4-AMINOPHENYLACETAMIDE | AstraZeneca AB (SE) | 2003-06-25 | — | — | EP | disclosed |
| WO-2002008247-A2 | PROCESS FOR THE PREPARATION OF 5-PHENYLPENTANOYL-ALA-ARGL-{2-[3-AMINO-2-OXOPYRROLIDIN-1-YL]PROPIONYL}-ALA-ARG-ALA-4-AMINOPHENYLACETAMIDE | ASTRAZENECA AB (SE) | 2002-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040101864-A1 | Chemical process | ASS1, SRM, SRMS | RAB9A 2009/4885NPC1 4657/4885SMN1; SMN2 2240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.